Related Experiment Video
Updated: Jan 19, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
Oncogenic RAS: From Its Activation to Its Direct Targeting
1Biomedical Sciences Program, Department of Life Sciences, School of Sciences, European University Cyprus, 1516 Nicosia, Cyprus.
Abstract:
The RAS oncogenes are the most commonly mutated genes across human cancers. This review is a look back at the discovery of the RAS genes, how we came to understand their function, and how these oncogenes are aberrantly activated, driving cancer development and growth. It also highlights the comprehensive efforts made during the last 30 years to develop therapeutic strategies against the oncogenic mutant RAS. Although there have been many lost battles in the war against mutant RAS-bearing cancer cells, and we have yet to determine which is the "best" path for inhibition of the mutated RAS, a better understanding of the protein's structure combined with technological advances in the field has allowed the development of new strategies to make anti-RAS therapies a reality. The state-of-the-art for each strategy is discussed, focusing on the promises and potential pitfalls of each of them.
Insights
RAS oncogenes are frequently mutated in cancer. This review covers RAS gene discovery, function, aberrant activation in cancer, and 30 years of therapeutic strategies, highlighting new anti-RAS therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- RAS oncogenes are the most frequently mutated genes in human cancers.
- Aberrant activation of RAS drives cancer development and progression.
- Targeting mutant RAS has been a significant challenge in cancer therapy.
Purpose of the Study:
- To review the discovery and function of RAS genes.
- To examine the mechanisms of RAS oncogene activation in cancer.
- To highlight therapeutic strategies developed over 30 years to target mutant RAS.
Main Methods:
- Literature review of RAS gene discovery and function.
- Analysis of mechanisms of oncogenic RAS activation.
- Overview of therapeutic strategies and their state-of-the-art.
Main Results:
- RAS genes play a critical role in cancer development.
- Despite challenges, advances in understanding RAS structure and technology enable new anti-RAS therapies.
- Various strategies show promise but also have potential pitfalls.
Conclusions:
- Targeting mutant RAS remains a key goal in oncology.
- New therapeutic strategies are emerging, offering hope for effective anti-RAS treatments.
- Continued research is essential to overcome challenges and optimize anti-RAS therapies.
More Related Videos
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
Related Concept Videos
The Ras Gene
Ras is a...
MAPK Signaling Cascades
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation